An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus.

Trial Profile

An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Antihypercalcaemics
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 15 Sep 2017 Results assessing the association between increases in plasma ketones and cardiovascular outcomes in canagliflozin treated subjects (n=1278), presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 10 Jun 2017 Biomarkers information updated
    • 03 Nov 2015 Results of post-hoc subgroup analyses (n=1299) published in the Advances in Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top